Hyper-Early Prevention and Diagnosis Unit

What does the Unit treat?

At HM CIOCC, the Hyper-Early Prevention and Diagnosis Unit is dedicated to the early detection of cancer, even before symptoms appear. We are an internationally recognized reference unit, unique in Europe, specializing in the hyper-early diagnosis of tumor processes in asymptomatic individuals aged 45 and over. We understand that early detection is key to successful treatment and increased survival, and that is why we offer a comprehensive approach to risk assessment, early diagnosis, and personalized management.

What makes us different?

• Comprehensive approach: We offer a complete program, from risk assessment to diagnosis and follow-up.
• Cutting-edge technology: We use the latest imaging and biomarker technologies to detect cancer in its earliest stages.
• Leaders in research: We develop advanced research projects in the international validation of new diagnostic tests in liquid biopsy, cross-reactivity studies, and minimal residual disease.

Related Diseases

All types of cancer, including:

• Breast cancer.
• Lung cancer.
• Colon cancer.
• Prostate cancer.
• Ovarian cancer.
• Melanoma.
• Etc.

Who is it for?

• People with a family history of cancer or with risk factors for developing cancer (smoking, obesity, exposure to carcinogens, etc.).
• Asymptomatic individuals aged 45 and over who wish to undergo a comprehensive check-up to detect cancer in its earliest stages.

What do we offer?

Cutting-edge non-invasive tests (liquid biopsy):

• Blood or urine tests to detect tumor components.
• Detection of genomic information from cancer cells.
• Identification of proteins produced by cancer cells.
• “Unitumoral” tests for specific cancers (colorectal, pancreas, breast, prostate, lung, urothelial, thyroid, oncohematological neoplasms).
• “Multitumoral” tests that detect multiple cancers simultaneously.